MedTrace Logo

National Data Bank for Rheumatic Disease Registry Study of Safety in Patients With Rheumatoid Arthritis Treated With Cimzia® or Disease-modifying Antirheumatic Drugs (DMARDs)

NCT01095393 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12500

Last updated 2020-07-16

No results posted yet for this study

Summary

Observational registry to assess the longer-term risk of serious infections and malignancies reported with TNFα-blocker therapy, as well as the longer-term risk of cardiovascular and thromboembolic events in adult Rheumatoid Arthritis (RA) patients treated with Cimzia® as compared to non-biologic DMARD-treated controls.

Conditions

Sponsors & Collaborators

  • National Data Bank for Rheumatic Diseases (NDB)

    collaborator OTHER

  • UCB Pharma

    lead INDUSTRY

Principal Investigators

  • Frederick Wolfe, M.D. · National Data Bank for Rheumatic Disease

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-01
Primary Completion
2016-12-13
Completion
2019-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01095393 on ClinicalTrials.gov